XOMA Reports Q4 2025 Earnings with Strong Royalty Receipts and Portfolio Expansion
XOMA reported strong financial results for Q4 2025, including a significant increase in royalty receipts driven by VABYSMO, OJEMDA, and MIPLYFFA. The company added new portfolio assets and executed share buybacks while restructuring its Takeda deal to diversify revenue sources.
Tickers: $XOMA
Topics: biotech royalties pharmaceuticals portfolio expansion share buybacks